<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03383016</url>
  </required_header>
  <id_info>
    <org_study_id>PCa19</org_study_id>
    <secondary_id>GRéPEC-17409</secondary_id>
    <nct_id>NCT03383016</nct_id>
  </id_info>
  <brief_title>Diet, Physical Activity and Related Candidate Biomarkers in Relation to Prostate Cancer Risk (BIOCaPPE)</brief_title>
  <acronym>BIOCaPPE</acronym>
  <official_title>Interaction Between Environment, Diet, Physical Activities, and Sexual Habits, in the Risk of Prostate Cancer. Validation of Biomarkers to Personalize Preventive Interventions (BIOCaPPE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McGill University Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de Recherche du Centre Hospitalier de l'Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CHU de Quebec-Universite Laval</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The risk of prostate cancer is associated with lifestyle habits, such as diet and physical
      activity. Indeed, results of numerous studies suggest links between obesity, diabetes,
      inflammation and androgen and estrogen metabolism in the pathogenesis of prostate cancer.

      The goal of BIOCaPPE study (Biomarkers and Prostate Cancer/ Prevention and Environment) is to
      identify biomarkers of prostate cancer risk that are potentially modifiable by environmental
      exposures (e.g. diet and physical activity).

      A selection of few of the most promising biological markers will be evaluated in a cohort of
      more than 3000 men at high-risk of prostate cancer.

      Such biomarkers would provide a practical approach to identify men at high risk of prostate
      cancer who could benefit from interventions aiming at reducing their risk. The biomarkers
      would also be useful to monitor the efficacy of the interventions on patient's lifestyle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of the proposed research project is to assess the association between five
      candidate biological markers potentially modifiable by environmental exposures (diet and
      physical activity) and the two-year risk of prostate cancer in a newly recruited cohort of
      men at high-risk of prostate cancer showing no evidence of cancer.

      Four hospitals in the province of Quebec (Canada) participate to the recruitment of 3,080 men
      at high-risk for prostate cancer, i.e. men who had a first negative prostate biopsy or whose
      Prostatic Specific Antigen (PSA) level is between 2.5 and 10 ng / ml without previous
      prostate biopsy.

      The candidate biomarkers that will be tested are:

        1. The ratio of ω-3/ ω-6 fatty acid content of red blood cell membranes,

        2. Oxidized low density lipoprotein cholesterol

        3. Adiponectin

        4. Insulin growth factor-1

        5. The ratio of dihydrotestosterone glucuronide derivatives over estradiol

      A biobank, composed of biological material (whole blood, plasma, serum, lymphocyte layer and
      excess tissue collected from prostate biopsy or prostate surgery) and clinical data is being
      created. Questionnaires are used to compile information on socio-demographic aspects, family
      and personal medical history, quality of life, lifestyle like food and sexual habits.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2013</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarkers and modifiable exposure environment</measure>
    <time_frame>An average of 2 years</time_frame>
    <description>Assess the association between five candidate biological markers potentially modifiable by environmental exposures, mainly diet and physical activity, with the two-year risk of prostate cancer in men at risk for prostate cancer as previously defined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study biobank</measure>
    <time_frame>Through study completion, every year up to 2 years</time_frame>
    <description>Biobank of biological samples, clinical data and data from the lifestyle questionnaires</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3080</enrollment>
  <condition>Epidemiology</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Men at high-rik of prostate cancer</arm_group_label>
    <description>Lifestyle questionnaires such as diet questionnaire, physical activities questionnaires, quality of life , Follows up 1 year and 2 years after the enrollment, Anthropometric measures during the first visit , Blood withdrawal for laboratory biomarkers analysis After 2 years, proposal for a 2-year end-of-study prostate biopsy to assess the presence or absence of prostate cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lifestyle questionnaires</intervention_name>
    <arm_group_label>Men at high-rik of prostate cancer</arm_group_label>
    <other_name>Blood withdrawal for Laboratory biomarkers analysis</other_name>
    <other_name>Anthropometric measures</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Prostate Biopsy</intervention_name>
    <description>Possible follow-up by an urologist at 1 year and 2 years after recruitment. After 2 years, proposal for a 2-year end-of-study prostate biopsy to assess the presence or absence of prostate cancer.</description>
    <arm_group_label>Men at high-rik of prostate cancer</arm_group_label>
    <other_name>follow-up by an urologist</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, plasma, whole blood and blood DNA samples and excess tissue collected from prostate
      biopsy or prostate surgery
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible participants for this prospective cohort study are men at risk for prostate
        cancer.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Group 1: serum-PSA level≥ 2.5 ng/L and a first negative prostate biopsy within 6
             months

          -  Group 2: serum-PSA level between 2.5- 10 ng/ml and no prior prostate biopsy

        Exclusion Criteria:

          -  Prostate cancer

          -  Positive result for transurethral prostatic resection
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves FRADET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Québec-Université Laval</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurence V. BETTAN, Ph.D</last_name>
    <phone>418-525-4444</phone>
    <phone_ext>16848</phone_ext>
    <email>Laurence.Bettan@crchudequebec.ulaval.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alain BERGERON, Ph.D</last_name>
    <phone>418-525-4444</phone>
    <phone_ext>15530</phone_ext>
    <email>Alain.Bergeron@crchudequebec.ulaval.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de Recherche du Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène Léonard, MS</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>26161</phone_ext>
      <email>helene.leonard.chum@ssss.gouv.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Brigitte Brisson, IA</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>24564</phone_ext>
      <email>brigitte.brisson.chum@ssss.gouv.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Fred SAAD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ginette McKercher, MS</last_name>
      <phone>514-928-1322</phone>
      <email>ginette.mckercher@mail.mcgill.ca</email>
    </contact>
    <contact_backup>
      <last_name>Nathalie Côté, BSN</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>44279</phone_ext>
      <email>nathalie.cote2@mail.mcgill.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Armen APRIKIAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec- Université Laval</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1R3S1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence V Bettan, Ph.D</last_name>
      <phone>418-525-4444</phone>
      <phone_ext>16848</phone_ext>
      <email>Laurence.Bettan@crchudequebec.ulaval.ca</email>
    </contact>
    <contact_backup>
      <last_name>Alain Bergeron, Ph.D</last_name>
      <phone>418-525-4444</phone>
      <phone_ext>15530</phone_ext>
      <email>Alain.Bergeron@crchudequebec.ulaval.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Yves Fradet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elsie Morneau, BSN</last_name>
      <phone>819-346-1110</phone>
      <phone_ext>12827</phone_ext>
      <email>emorneau.chus@ssss.gouv.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Nathalie Goudreau, BAA</last_name>
      <phone>819-346-1110</phone>
      <phone_ext>12810</phone_ext>
      <email>ngoudreau.chus@ssss.gouv.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Michel CARMEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2017</study_first_submitted>
  <study_first_submitted_qc>December 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate cancer risk</keyword>
  <keyword>Environmental risk factors</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Inflammation and prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

